Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " February 23, 2011":" March 25, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Enhancement of Connect to Protect® (C2P)
Condition: HIV Infection
Intervention: Behavioral: Community Mobilization
2 Unknown  CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements
Condition: HIV
Intervention: Dietary Supplement: Immunolin®
3 Completed Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Condition: HIV Infection
Interventions: Drug: Ritonavir boosted Atazanavir + Lamivudine;   Drug: Ritonavir boosted Atazanavir + 2 NRTIs
4 Completed Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
Condition: HIV Infection
Intervention:
5 Active, not recruiting The VMVN Study: Virological Monitoring in Viet Nam
Conditions: HIV Infection;   AIDS
Interventions: Other: Standard Care;   Other: Virological Monitoring
6 Unknown  Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients
Conditions: HBV Coinfection;   HIV Infections
Interventions: Drug: raltegravir and tenofovir and lamivudine;   Drug: efavirenz+tenofovir+lamivudine
7 Completed EuroSIDA As An External Comparator To MOTIVATE Trials
Conditions: HIV;   AIDS
Intervention: Other: maraviroc
8 Completed Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM)
Condition: Acquired Immunodeficiency Syndrome
Intervention: Behavioral: Focus Group
9 Completed
Has Results
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: EFV/FTC/TDF
10 Completed
Has Results
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
Condition: HIV Coinfection
Interventions: Drug: Maraviroc;   Drug: Placebo
11 Completed The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
Condition: HIV
Intervention: Drug: Maraviroc
12 Completed Drug Interactions Between Echinacea Purpurea and Etravirine
Condition: HIV
Intervention: Dietary Supplement: Echinacea purpurea
13 Completed The Raltegravir 60+ Study
Condition: HIV
Intervention: Drug: Raltegravir
14 Completed Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine
Condition: HIV
Interventions: Biological: Investigational HIV vaccine dose A;   Biological: Investigational HIV vaccine dose B
15 Completed The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Conditions: HIV Infection;   Cardiovascular Disease;   Inflammation
Intervention:
16 Completed Managerial Database II
Condition: Acquired Immunodeficiency Syndrome
Intervention:
17 Enrolling by invitation HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation
Conditions: HIV Infection;   AIDS;   Cirrhosis
Intervention: Procedure: Hematopoietic stem cell transplantation
18 Completed Progress Pediatric Study
Conditions: HIV;   Depression
Intervention: Drug: standard ART according to the Thai Ministry of Public Health national guidelines
19 Completed Progress Adult Study
Conditions: HIV;   Depression
Intervention: Drug: standard regimens according to the Thai Ministry of Public Health national guidelines
20 Completed Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
Conditions: HCV Coinfection;   HIV-1 Infection
Intervention: Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.